Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are
increasingly being used as preventive treatments for migraine. Their effectiveness and …

Background Headache disorders are a global public health concern affecting diverse
populations. This review examines headache service organizations in low-, middle-, and …

After 35 years since the introduction of the International Classification of Headache
Disorders (ICHD), we are living in the era of the second great revolution in migraine …

Background Real-world data on the effectiveness of calcitonin gene-related peptide
monoclonal antibodies (CGRP mAbs) in migraine patients are needed. Methods We …

Objective To provide a position statement update from The American Headache Society
specifically regarding therapies targeting calcitonin gene‐related peptide (CGRP) for the …

Objective To prospectively assess the efficacy and safety of fremanezumab for migraine
prophylaxis in patients with failure of at least three previous preventive treatments. Changes …

Abstract Purpose of Review Real-world data (RWD) has identified potential predictors of
response to anti-CGRP therapies in patients with chronic migraine (CM). This review aims to …

Background Randomized clinical trials have demonstrated efficacy and safety of erenumab.
The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world …

Objective: To define, in a real-world population of patients with high-frequency episodic
(HFEM) or chronic migraine (CM), the predictive role of socio-demographic or phenotypic …

Background Many risk factors have been associated with migraine progression, including
insufficient and ineffective utilization of migraine medications; however, they have been …